This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gómez-Varela, D. Articles by Pardo, L. A. Search for Related Content PubMed PubMed Citation Articles by Gómez-Varela, D. Articles by Pardo, L. A.

Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumor Activity

¹ Max-Planck Institute of Experimental Medicine, and ² iOnGen AG, Göttingen, Germany; and ³ U3 Pharma AG, Martinsried, Germany

Requests for reprints: Luis Pardo, Max-Planck Institute of Experimental Medicine, Hermann-Rein-Str. 3, 37075 Göttingen, Germany. E-mail: pardo{at}em.mpg.de.

The potassium channel ether à go-go has been directly linked to cellular proliferation and transformation, although its physiologic role(s) are as of yet unknown. The specific blockade of human Eag1 (hEag1) may not only allow the dissection of the role of the channel in distinct physiologic processes, but because of the implication of hEag1 in tumor biology, it may also offer an opportunity for the treatment of cancer. However, members of the potassium channel superfamily are structurally very similar to one another, and it has been notoriously difficult to obtain specific blockers for any given channel. Here, we describe and validate the first rational design of a monoclonal antibody that selectively inhibits a potassium current in intact cells. Specifically blocking hEag1 function using this antibody inhibits tumor cell growth both in vitro and in vivo. Our data provide a proof of concept that enables the generation of functional antagonistic monoclonal antibodies against ion channels with therapeutic potential. The particular antibody described here, as well as the technique developed to make additional functional antibodies to Eag1, makes it possible to evaluate the potential of the channel as a target for cancer therapy. [Cancer Res 2007;67(15):7343–49]

This article has been cited by other articles:

				L. Diaz, I. Ceja-Ochoa, I. Restrepo-Angulo, F. Larrea, E. Avila-Chavez, R. Garcia-Becerra, E. Borja-Cacho, D. Barrera, E. Ahumada, P. Gariglio, et al. Estrogens and Human Papilloma Virus Oncogenes Regulate Human Ether-a-go-go-1 Potassium Channel Expression Cancer Res., April 15, 2009; 69(8): 3300 - 3307. [Abstract] [Full Text] [PDF]

				B. R. Downie, A. Sanchez, H. Knotgen, C. Contreras-Jurado, M. Gymnopoulos, C. Weber, W. Stuhmer, and L. A. Pardo Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in Tumors J. Biol. Chem., December 26, 2008; 283(52): 36234 - 36240. [Abstract] [Full Text] [PDF]

				A. Schwab, P. Hanley, A. Fabian, and C. Stock Potassium Channels Keep Mobile Cells on the Go Physiology, August 1, 2008; 23(4): 212 - 220. [Abstract] [Full Text] [PDF]

				A. Becchetti and A. Arcangeli A Comment on Ion Channels as Pharmacological Targets in Oncology J. Gen. Physiol., July 28, 2008; 132(2): 313 - 314. [Full Text] [PDF]

				L. A. Pardo and W. Stuhmer Eag1: An Emerging Oncological Target Cancer Res., March 15, 2008; 68(6): 1611 - 1613. [Abstract] [Full Text] [PDF]